{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:37Z","timestamp":1793499997971,"version":"4.5.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"18","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:p>Immune checkpoint inhibitors have transformed treatment paradigms in multiple tumor types including triple-negative breast cancer. However, clinical benefit in metastatic disease is restricted to patients with PD-L1\u2013positive tumors, and primary and acquired resistance remains common among treated patients. These challenges have prompted interest in novel immune checkpoints such as V-domain immunoglobulin suppressor of T-cell activation (VISTA), a B7 family protein with complex immunoregulatory functions. Although VISTA is expressed in multiple tumor types and increasingly explored as a therapeutic target, its exact signaling mechanisms remain unclear. In this issue of Cancer Research, Zhao and colleagues demonstrated that VISTA suppresses tumor growth in a subset of VISTA-expressing triple-negative breast cancers via a cell-intrinsic, immune-independent mechanism. They discovered a conserved four\u2013amino acid motif (NPGF) in VISTA\u2019s intracellular domain that mediates its antiproliferative effects by recruiting and sequestering the adapter protein NUMB at endosomes, thereby impairing trafficking of multiple growth factor receptors. VISTA-expressing tumors exhibit marked sensitivity to VISTA-blocking antibodies, a response that depends on the presence of the NPGF motif. Together, these findings redefine VISTA as a cell-intrinsic regulator of tumor growth and introduce new potential therapeutic avenues that extend beyond receptor\u2013ligand disruption to interfere with checkpoint-mediated intracellular trafficking and signaling.<\/jats:p>\n                  <jats:p>See related article by Zhao et al., p. 3399<\/jats:p>","DOI":"10.1158\/0008-5472.can-25-2286","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:08:01Z","timestamp":1757920081000},"page":"3371-3372","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A New VISTA in Intracellular Checkpoint Signaling in Triple-Negative Breast Cancer"],"prefix":"10.1158","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1806-1269","authenticated-orcid":false,"given":"Jacqueline J.","family":"Tao","sequence":"first","affiliation":[{"name":"1Columbia University Irving Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1779-484X","authenticated-orcid":false,"given":"Neil","family":"Vasan","sequence":"additional","affiliation":[{"name":"1Columbia University Irving Medical Center, New York, New York."},{"name":"2Department of Medicine, New York University Grossman School of Medicine, New York, New York."},{"name":"3Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2025091503074965300_bib1","first-page":"3223","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat Med"},{"key":"2025091503074965300_bib2","first-page":"RF3","article-title":"Abstract RF3-03: Nivolumab + Ipilimumab (NIVO + IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy \u2013 final results of BreastImmune-03, a multicenter randomized open-label phase II trial","volume":"31","author":"Tr\u00e9dan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025091503074965300_bib3","first-page":"24","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025091503074965300_bib4","first-page":"102942","article-title":"Viewing the immune checkpoint VISTA: landscape and outcomes across cancers","volume":"9","author":"Nishizaki","year":"2024","journal-title":"ESMO Open"},{"key":"2025091503074965300_bib5","first-page":"551","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"2025091503074965300_bib6","first-page":"3399","article-title":"VISTA-induced tumor suppression by a four amino acid intracellular motif","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Res"},{"key":"2025091503074965300_bib7","first-page":"333","article-title":"The multitasker protein: a look at the multiple capabilities of NUMB","volume":"12","author":"Ortega-Campos","year":"2023","journal-title":"Cells"},{"key":"2025091503074965300_bib8","first-page":"A793","article-title":"Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 Anti-VISTA antibody in patients with advanced solid tumors","volume":"10","author":"Noelle","year":"2022","journal-title":"J ImmunoTherapy of Cancer"},{"key":"2025091503074965300_bib9","first-page":"TPS2664","article-title":"A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors","volume":"41","author":"Rodon Ahnert","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025091503074965300_bib10","first-page":"1311658","article-title":"A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors","volume":"14","author":"Iadonato","year":"2023","journal-title":"Front Immunol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/18\/3371\/3647540\/can-25-2286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/18\/3371\/3647540\/can-25-2286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:08:01Z","timestamp":1757920081000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/85\/18\/3371\/764446\/A-New-VISTA-in-Intracellular-Checkpoint-Signaling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":10,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9,15]]},"published-print":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-2286","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}